nach oben

Erschienen in:

25.01.2019 | Article

Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study

verfasst von: Natasha C. Bergmann, Asger Lund, Lærke S. Gasbjerg, Emma C. E. Meessen, Maria M. Andersen, Sigrid Bergmann, Bolette Hartmann, Jens J. Holst, Lene Jessen, Mikkel B. Christensen, Tina Vilsbøll, Filip K. Knop

Erschienen in: Diabetologia | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

Glucagon-like peptide 1 (GLP-1) reduces appetite and energy intake in humans, whereas the other incretin hormone, glucose-dependent insulinotropic polypeptide (GIP), seems to have no effect on eating behaviour. Interestingly, studies in rodents have shown that concomitant activation of GIP and GLP-1 receptors may potentiate the satiety-promoting effect of GLP-1, and a novel dual GLP-1/GIP receptor agonist was recently shown to trigger greater weight losses compared with a GLP-1 receptor agonist in individuals with type 2 diabetes. The aim of this study was to delineate the effects of combined GIP and GLP-1 receptor activation on energy intake, appetite and resting energy expenditure in humans.

Methods

We examined 17 overweight/obese men in a crossover design with 5 study days. On day 1, a 50 g OGTT was performed; on the following 4 study days, the men received an isoglycaemic i.v. glucose infusion (IIGI) plus saline (154 mmol/l NaCl; placebo), GIP (4 pmol kg⁻¹ min⁻¹), GLP-1 (1 pmol kg⁻¹ min⁻¹) or GIP+GLP-1 (4 and 1 pmol kg⁻¹ min⁻¹, respectively). All IIGIs were performed in a randomised order blinded for the participant and the investigators. The primary endpoint was energy intake as measured by an ad libitum meal after 240 min. Secondary endpoints included appetite ratings and resting energy expenditure, as well as insulin, C-peptide and glucagon responses.

Results

Energy intake was significantly reduced during IIGI+GLP-1 compared with IIGI+saline infusion (2715 ± 409 vs 4483 ± 568 kJ [mean ± SEM, n = 17], p = 0.014), whereas there were no significant differences in energy intake during IIGI+GIP (4062 ± 520 kJ) or IIGI+GIP+GLP-1 (3875 ± 451 kJ) infusion compared with IIGI+saline (p = 0.590 and p = 0.364, respectively). Energy intake was higher during IIGI+GIP+GLP-1 compared with IIGI+GLP-1 infusion (p = 0.039).

Conclusions/interpretation

While GLP-1 infusion lowered energy intake in overweight/obese men, simultaneous GIP infusion did not potentiate this GLP-1-mediated effect.

Trial registration

ClinicalTrials.gov NCT02598791

Funding

This study was supported by grants from the Innovation Fund Denmark and the Vissing Foundation.

Nur mit Berechtigung zugänglich

Campbell JE, Drucker DJ (2013) Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 17(6):819–837. https://doi.org/10.1016/j.cmet.2013.04.008 CrossRefPubMed

Flint A, Raben A, Astrup A, Holst JJ (1998) Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101(3):515–520. https://doi.org/10.1172/JCI990 CrossRefPubMedPubMedCentral

Flint A, Raben A, Ersbøll AK et al (2001) The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord 25(6):781–792. https://doi.org/10.1038/sj.ijo.0801627 CrossRefPubMed

Shalev A, Holst JJ, Keller U (1997) Effects of glucagon-like peptide 1 (7-36 amide) on whole-body protein metabolism in healthy man. Eur J Clin Investig 27:10–16CrossRef

Horowitz M, Flint A, Jones KL et al (2012) Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Diabetes Res Clin Pract 97(2):258–266. https://doi.org/10.1016/j.diabres.2012.02.016 CrossRefPubMed

Asmar M, Tangaa W, Madsbad S et al (2010) On the role of glucose-dependent insulintropic polypeptide in postprandial metabolism in humans. Am J Physiol Endocrinol Metab 298(3):E614–E621. https://doi.org/10.1152/ajpendo.00639.2009 CrossRefPubMed

Finan B, Ma T, Ottaway N et al (2013) Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med 5(209):209ra151. https://doi.org/10.1126/scitranslmed.3007218 CrossRefPubMed

Gault VA, Kerr BD, Harriott P, Flatt PR (2011) Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with type 2 diabetes and obesity. Clin Sci (Lond) 121(3):107–117. https://doi.org/10.1042/CS20110006 CrossRef

Nørregaard PK, Deryabina MA, Tofteng Shelton P et al (2017) A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents. Diabetes Obes Metab 20(1):1–9. https://doi.org/10.1111/dom.13034 CrossRef

10.

Daousi C, Wilding JPH, Aditya S et al (2009) Effects of peripheral administration of synthetic human glucose-dependent insulinotropic peptide (GIP) on energy expenditure and subjective appetite sensations in healthy normal weight subjects and obese patients with type 2 diabetes. Clin Endocrinol 71(2):195–201. https://doi.org/10.1111/j.1365-2265.2008.03451.x CrossRef

11.

Ørskov C, Rabenhøj L, Wettergren A et al (1994) Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43(4):535–539. https://doi.org/10.2337/diab.43.4.535 CrossRefPubMed

12.

Lindgren O, Carr RD, Deacon CF et al (2011) Incretin hormone and insulin responses to oral versus intravenous lipid administration in humans. J Clin Endocrinol Metab 96(8):2519–2524. https://doi.org/10.1210/jc.2011-0266 CrossRefPubMed

13.

Gregersen NT, Flint A, Bitz C et al (2008) Reproducibility and power of ad libitum energy intake assessed by repeated single meals. Am J Clin Nutr 87(5):1277–1281. https://doi.org/10.1093/ajcn/87.5.1277 CrossRefPubMed

14.

Hovorka R, Soons PA, Young MA (1996) ISEC: a program to calculate insulin secretion. Comput Methods Prog Biomed 50(3):253–264. https://doi.org/10.1016/0169-2607(96)01755-5 CrossRef

15.

Blundell J, Finlayson G, Axelsen M et al (2017) Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab 19(9):1242–1251. https://doi.org/10.1111/dom.12932 CrossRefPubMedPubMedCentral

16.

Näslund E, Barkeling B, King N et al (1999) Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 23(3):304–311. https://doi.org/10.1038/sj.ijo.0800818 CrossRefPubMed

17.

Chaput J-P, Tremblay A (2009) The glucostatic theory of appetite control and the risk of obesity and diabetes. Int J Obes 33(1):46–53. https://doi.org/10.1038/ijo.2008.221

18.

Vilsbøll T, Agersø H, Lauritsen T et al (2006) The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects. Regul Pept 137(3):168–172. https://doi.org/10.1016/j.regpep.2006.07.007 CrossRefPubMed

19.

Vilsbøll T, Agersø H, Krarup T, Holst JJ (2003) Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 88(1):220–224. https://doi.org/10.1210/jc.2002-021053 CrossRefPubMed

20.

Verdich C, Flint A, Gutzwiller J-P et al (2001) A meta-analysis of the effect of glucagon-like peptide-1 (7–36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 86:4382–4389PubMed

21.

Mentis N, Vardarli I, Köthe LD et al (2011) GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes. Diabetes 60(4):1270–1276. https://doi.org/10.2337/db10-1332 CrossRefPubMedPubMedCentral

22.

Schmitt C, Portron A, Jadidi S et al (2017) Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 in people with type 2 diabetes mellitus. Diabetes Obes Metab 19(10):1436–1445. https://doi.org/10.1111/dom.13024

23.

Frias JP, Bastyr EJ, Vignati L et al (2017) The sustained effects of a dual GIP/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes. Cell Metab 26(2):343–352.e2. https://doi.org/10.1016/j.cmet.2017.07.011 CrossRefPubMed

24.

Frias JP, Nauck MA, Van J et al (2018) Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet 392(10160):2180–2193. https://doi.org/10.1016/S0140-6736(18)32260-8 CrossRefPubMed

25.

DiMarchi RD (2018) “Let’s stay together”; GIP and GLP-1 dual agonism in the treatment of metabolic disease. Mol Metab 18:1–2. https://doi.org/10.1016/J.MOLMET.2018.10.004 CrossRefPubMedPubMedCentral

26.

Finan B, Müller TD, Clemmensen C et al (2016) Reappraisal of GIP pharmacology for metabolic diseases. Trends Mol Med 22(5):359–376. https://doi.org/10.1016/j.molmed.2016.03.005 CrossRefPubMed

27.

Miyawaki K, Yamada Y, Ban N et al (2002) Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 8(7):738–742. https://doi.org/10.1038/nm727 CrossRefPubMed

28.

McClean PL, Irwin N, Cassidy RS et al (2007) GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. Am J Physiol Endocrinol Metab 293(6):E1746–E1755. https://doi.org/10.1152/ajpendo.00460.2007 CrossRefPubMed

29.

Althage MC, Ford EL, Wang S et al (2008) Targeted ablation of glucose-dependent insulinotropic polypeptide-producing cells in transgenic mice reduces obesity and insulin resistance induced by a high fat diet. J Biol Chem 283(26):18365–18376. https://doi.org/10.1074/jbc.M710466200 CrossRefPubMedPubMedCentral

30.

Kim SJ, Nian C, Karunakaran S et al (2012) GIP-overexpressing mice demonstrate reduced diet-induced obesity and steatosis, and improved glucose homeostasis. PLoS One 7(7):e40156. https://doi.org/10.1371/journal.pone.0040156 CrossRefPubMedPubMedCentral

31.

Sparre-Ulrich AH, Hansen LS, Svendsen B et al (2016) Species-specific action of (Pro3)GIP – a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors. Br J Pharmacol 173(1):27–38. https://doi.org/10.1111/bph.13323 CrossRefPubMed

32.

Vilsbøll T, Knop FK, Krarup T et al (2003) The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide – regardless of etiology and phenotype. J Clin Endocrinol Metab 88(10):4897–4903. https://doi.org/10.1210/jc.2003-030738 CrossRefPubMed

33.

Rudovich N, Pivovarova O, Gögebakan O et al (2015) Effect of exogenous intravenous administrations of GLP-1 and/or GIP on circulating pro-atrial natriuretic peptide in subjects with different stages of glucose tolerance. Diabetes Care 38(1):e7–e8. https://doi.org/10.2337/dc14-1452 CrossRefPubMed

34.

Elahi D, McAloon-Dyke M, Fukagawa NK et al (1994) The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7–37) in normal and diabetic subjects. Regul Pept 51(1):63–74. https://doi.org/10.1016/0167-0115(94)90136-8 CrossRefPubMed

35.

Nauck MA, Bartels E, Orskov C et al (1993) Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 76:912–917PubMed

36.

Knop FK, Aaboe K, Vilsbøll T et al (2012) Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity. Diabetes Obes Metab 14(6):500–510. https://doi.org/10.1111/j.1463-1326.2011.01549.x CrossRefPubMed

37.

Calanna S, Piro S, Di Pino A et al (2013) Beta and alpha cell function in metabolically healthy but obese subjects: relationship with entero-insular axis. Obesity 21(2):320–325. https://doi.org/10.1002/oby.20017 CrossRefPubMed

Titel: Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study
verfasst von: Natasha C. Bergmann
Asger Lund
Lærke S. Gasbjerg
Emma C. E. Meessen
Maria M. Andersen
Sigrid Bergmann
Bolette Hartmann
Jens J. Holst
Lene Jessen
Mikkel B. Christensen
Tina Vilsbøll
Filip K. Knop
Publikationsdatum: 25.01.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Diabetologia / Ausgabe 4/2019
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-018-4810-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Trial registration

Funding

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Trial registration

Funding

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2019

Correction to: Adipokines and the insulin resistance syndrome in familial partial lipodystrophy caused by a mutation in lamin A/C

A future for CD3 antibodies in immunotherapy of type 1 diabetes

Beta cells in type 1 diabetes: mass and function; sleeping or dead?

Correction to: The discovery of novel predictive biomarkers and early-stage pathophysiology for the transition from gestational diabetes to type 2 diabetes

Referees 2018

Effect of duration and burden of microvascular complications on mortality rate in type 1 diabetes: an observational clinical cohort study

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin